Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

390results about How to "Avoid symptoms" patented technology

Methods and sequences to suppress primate huntington gene expression

Disclosed herein are sequences, molecules and methods used to suppress the expression of HD genes encoding for huntingtin protein in primates including Macaca mulatta and Homo sapiens. These sequences, molecules and methods aid in the study of the pathogenesis of HD and can also provide a treatment for this disease.
Owner:MEDTRONIC INC

One dose vaccination with Mycoplasma hyopneumoniae

InactiveUS6846477B2Preventing and reducing lung lesionMaintaining immunityAntibacterial agentsBiocideDiseaseVaccines Administered
The present invention relates to methods for treating or preventing a disease or disorder in an animal caused by infection by Mycoplasma hyopneumoniae (M. hyo) by administering to the animal at approximately three (3) to ten (10) days of age, a single dose of an effective amount of a M. hyo vaccine. The M. hyo vaccine can be a whole or partial cell inactivated or modified live preparation, a subunit vaccine, or a nucleic acid or DNA vaccine. The M. hyo vaccine administered in accordance with the present invention can be synthesized or recombinantly produced.
Owner:ZOETIS SERVICE LLC +1

Glp-1 and methods for treating diabetes

InactiveUS20060057137A1Prevent and treat diseasePrevent and treat and delay onset of and reduce symptomPeptide/protein ingredientsMetabolism disorderDiseaseDiabetes mellitus
The present invention relates to use of GLP-1 or a related molecule having GLP-effect for the manufacture of a medicament for preventing or treating diabetes in a mammal. The amount and timing of administration of said medicament are subsequently reduced to produce a “drug holiday”. Practice of the invention achieves effective therapy without continuous drug exposure and without continuous presence of therapeutic levels of the drug. The invention also discloses a method of treating diabetes and related disorders in a mammal by administering glucagons like peptide (GLP-1) or a related molecule having GLP-1 like effect and thereby providing a therapeutically effective amount of endogenous insulin.
Owner:ZEALAND PHARM AS

Methods and compositions for treating benign gynecological disorders

InactiveUS6960337B2Increased riskPrevent endometrial hyperplasiaOrganic active ingredientsBiocideDiseaseGynecology
An improvement in a method of treating benign gynecological disorders is described. In the method, treatment of a benign gynecological disorder with a composition comprised of a gonadotropin releasing hormone (GnRH) compound and an estrogenic compound, and optionally, an androgenic compound, is extended to premenopausal women who are not receiving an exogenously supplied progestin on a regular or periodic basis. Treatment in accord with the invention does not increase significantly the risk of endometrial hyperplasia. The method is also suitable for contraception.
Owner:BALANCE PHARMA

Methods of modulating immune function

Presented herein are therapeutic agents that modulate one or more immune functions and uses of such therapeutic agents in the prevention, treatment and management of diseases. In one aspect, the therapeutic agents modulate one or more signal transduction pathways induced by the binding of B7-H7 to B7-H7CR, or the binding of B7-H2 to either ICOS, CD28, or CTLA-4. In another aspect, the therapeutic agents modulate the binding of B7-H7 to B7-H7CR, or the binding of B7-H2 to either ICOS, CD28, or CTLA-4. The therapeutic agents can be used in the prevention, treatment and / or management of diseases in which it might be useful to modulate one or more immune functions (e.g., cancer, infectious disease, autoimmune disease, and transplantation rejection). In another aspect, presented herein are methods for identifying receptor-ligand interactions.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE

Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections

A novel method of treating and preventing bacterial diseases is provided. In particular, the present invention relates to compositions and methods for inhibition of Gram negative, Gram positive and acid fast bacilli in general and tuberculosis (TB), mycobacterium avium complex (MAC), and anthrax in particular. Thus, the invention relates to modulation of cellular activities, including macrophage activity, and the like. More particularly, the present invention relates to the inhibitory compounds comprising naturally occurring and man-made inhibitors of serine protease.
Owner:UNIV OF COLORADO THE REGENTS OF

Lysine demethylase inhibitors for inflammatory diseases or conditions

InactiveUS20140329833A1Reduce plateletAvoids side-effectsBiocideOrganic chemistryAmine derivativesInflammation
The invention relates to methods and compositions for the treatment or prevention of inflammation and inflammatory diseases or conditions. In particular, the invention relates to an LSD1 inhibitor, such as a 2-cyclylcylopropan-1-amine derivative, a phenelzine derivative and a propargylamine derivative, for use in treating or preventing inflammation and inflammatory diseases or conditions.
Owner:ORYZON GENOMICS SA

Cyclopropylamine derivatives useful as lsd1 inhibitors

InactiveUS20130303545A1Ameliorate symptomReduce declineBiocideNervous disorderDiseasePsychiatry
The invention relates to methods and compositions for the treatment or prevention of protein conformation disorders. In particular, the invention relates to an LSD1 inhibitor for use in treating or preventing a protein conformation disorder, such as, e.g., Huntington Disease.
Owner:ORYZON GENOMICS SA

Compositions and methods in the treatment of bone metabolic disorders

InactiveUS20070197573A1Block undesirable peripheral effectAvoid abuseBiocideAnimal repellantsDiseaseOpioid antagonist
Bone metabolic disorders are treated by administering to an individual a therapeutically effective amount of a peripheral opioid antagonist at one or more of the opioid receptors, including the various naloxone and naltrexone analogs or a pharmaceutically acceptable salt thereof. The invention is further embodied in the use of peripheral antagonists of the opioid receptors, such as the use of naltrexone and naloxone analogs, which can be opioid antagonist with peripheral selectivity at the μ opioid receptor, for the treatment of bone loss, osteoporosis, osteopenia and other bone disorders in individuals using opioid drugs, including patients using opioids for analgesia and in opioid drug-dependent individuals
Owner:AIKO BIOTECH

Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage

ActiveUS20110263504A1Prevent progression and worseningReduction in damage and effect and symptomAntibacterial agentsBacteriaDiseaseHaematopoiesis
The present invention provides peptides and peptide analogs that have tissue protective activities while having little or no potentially undesirable hematopoietic effects. The peptides and peptide analogs are useful in preventing and treating a variety of diseases and disorders associated with tissue damage.
Owner:ARAIM PHARMA INC

Barley for production of flavor-stable beverage

ActiveUS20050204437A1High activityIntensified flavorOxidoreductasesTea2-NonenalMetabolite
According to the invention, there is provided null-LOX-1 barley and plant products produced thereof, such as malt manufactured by using barley kernels defective in synthesis of the fatty acid-converting enzyme lipoxygenase-1. Said enzyme accounts for the principal activity related to conversion of linoleic acid into 9-hydroperoxy octadecadienoic acid, a lipoxygenase pathway metabolite, which—through further enzymatic or spontaneous reactions—may lead to the appearance of trans-2-nonenal. The invention enables brewers to produce a beer devoid of detectable trans-2-nonenal-specific off-flavors, even after prolonged storage of the beverage.
Owner:CARLSBERG BREWERIES AS

Failure detection method and device for nodes in cluster system

The embodiment of the invention provides a failure detection method and device for nodes in a cluster system. The method comprises the following steps that: a first node judges whether a first heartbeat message sent by a second node is received in preset time or not, wherein the first node is a neighbor node of the second node, and the first heartbeat message is a heartbeat message which is sent to each neighbor node of the second node in parallel by the second node; under the condition that the first node does not receive the heartbeat message sent by the second node, the first node sends a request message to other neighbor nodes other than the first node in all the neighbor nodes of the second node; the first node receives response messages carrying reception states sent by the other neighbor nodes; and under the condition that the first node determines that other neighbor nodes do not receive the heartbeat message according to the reception states, the first node determines that the second node fails. Through adoption of the failure detection method and device for the nodes in the cluster system, the node failure detection efficiency can be increased.
Owner:HUAWEI TECH CO LTD

Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response

Herpes Simplex Virus-2 (HSV-2) infection is a major health concern. The present disclosure provides, inter alia, certain highly effective vaccines and immunogenic compositions against HSV-2. The antigens can be used therapeutically or prophylactically.
Owner:RUNWAY ADVISORS LLC

Methods and compositions for induction or promotion of immune tolerance

InactiveUS20060193869A1Suppressing autoimmune responseSuppresses autoimmune responsePeptide/protein ingredientsGenetic material ingredientsImmune tolerancePolynucleotide
The invention provides non-immunostimulatory polynucleotide antigen conjugates and methods for treating unwanted immune reactions in individuals using the non-immunostimulatory polynucleotide antigen conjugates.
Owner:DYNAVAX TECH CORP

Menopause disorder synergistic phyto-nutraceutical composition

InactiveUS20080069909A1Increase risk of developPreventing symptomOrganic active ingredientsBiocideSide effectChemical composition
A Phytoceutical composition for the prevention and treatment of menopause disorders and symptoms is provided. A specific combination of extracts of plants is taught, as well as principles for varying the formulations based on categorizing plants into one of three groups, Energy, Bio-Intelligence, and Organization and selecting several plants from each group. Such combinations have synergistic effects, with minimal side effects.
Owner:OLALDE JOSE ANGEL

Methods and compositions for altering cell function

The present invention relates to compositions and methods for altering cell function. In particular, the present invention provides compositions comprising selenium (e.g., SEL-PLEX) and methods of using the same (e.g., as a therapeutic and / or prophylactic treatment for neurodegenerative disease). Additionally, the present invention demonstrates that specific forms of selenium (e.g., SEL-PLEX) possess the ability to alter expression of genes associated with disease and / or aging while other forms of selenium (e.g., selenomethionine) do not.
Owner:ALLTECH CO LTD

Intravaginal support devices and methods

The present disclosure, in certain embodiments, relates to a flexible and non-absorbent vaginal insert device that is easier to insert and remove and is for use in improving and preventing symptoms associated with pelvic organ prolapse and urinary and / or fecal incontinence when the device is inserted. In certain embodiments, the device has an optionally cone-shaped upper portion that provides pelvic organ support and a removal portion or stem that facilitates insertion and removal of the device.
Owner:WATKINS CONTI PROD INC

Treating vitamin D responsive diseases

The present invention relates to therapeutics for the prevention and treatment of vitamin D responsive diseases in humans, as well as other animals, through the use of biologically active vitamin D compounds in combination with at least one other immunomodulatory compound such as interleukin-10, interleukin-4, or a TNFα inhibitor.
Owner:WISCONSIN ALUMNI RES FOUND

Connective tissue derived polypeptides

InactiveUS20070105763A1Preventing symptomReduce severityPeptide/protein ingredientsAntipyreticAntigenCollagen Type IX
The present invention relates to compositions comprising one or more connective tissue derived polypeptides having a molecular weight of less than 30,000 Da that are capable of tolerising individuals to antigenic components of cartilage and prevent the appearance of and / or treat symptoms of arthritis and other musculoskeletal degenerative conditions. The present invention provides methods for recovering polypeptides having a molecular weight of less than 30,000 Da from connective tissue and having anti-arthritic or anti-inflammatory activity. The present invention further relates to compositions comprising a polypeptide containing an NC4 domain of collagen type IX alpha 1 chain or fragment thereof, having a molecular weight of less than 30,000 Da, where the polypeptide is capable of tolerising individuals to antigenic components of cartilage, preventing the appearance of arthritic symptoms, and / or treating the symptoms of arthritis.
Owner:PROTEOBIOACTIVES PTY LTD

SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF

The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the Serpinc1 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of Serpinc1 and methods of treating subjects having a bleeding disorder, such as a hemophilia.
Owner:GENZYME CORP

Methods for treating psychosis associated with interferson-alpha therapy

The present invention relates to the treatment of psychosis associated with interferon-therapy. The present invention further relates to kits for the treatment of Hepatitis C in a patient.
Owner:CORCEPT THERAPEUTICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products